Investors looking for stocks in the Computers - IT Services sector might want to consider either Leidos (LDOS) or Dynatrace (DT). But which of these two stocks presents investors with the better value opportunity right now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) and Zoetis (ZTS).

Investors interested in stocks from the Mining - Gold sector have probably already heard of Harmony Gold (HMY) and Franco-Nevada (FNV). But which of these two stocks is more attractive to value investors?

Investors interested in stocks from the Retail - Apparel and Shoes sector have probably already heard of Canada Goose (GOOS) and Industria de Diseno Textil SA (IDEXY). But which of these two stocks presents investors with the better value opportunity right now?

Investors interested in stocks from the Consumer Products - Staples sector have probably already heard of Ahold NV (ADRNY) and Clorox (CLX). But which of these two stocks presents investors with the better value opportunity right now?

Investors with an interest in Insurance - Life Insurance stocks have likely encountered both NN Group NV Unsponsored ADR (NNGRY) and The Baldwin Insurance Group (BWIN). But which of these two companies is the best option for those looking for undervalued stocks?

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Meta Platforms, Inc.("Meta" or the "Company") (NASDAQ:META). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Photronics, Inc. ("Photronics" or the "Company") (NASDAQ:PLAB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Apple Inc.("Apple" or the "Company") (NASDAQ:AAPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Eos Energy Enterprises, Inc. ("Eos" or the "Company") (NASDAQ:EOSE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. ("Semler" or the "Company") (NASDAQ:SMLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.

Dollar Tree, Inc. (NASDAQ:DLTR ) Q1 2025 Earnings Conference Call June 4, 2025 8:00 AM ET Company Participants Michael C. Creedon - CEO & Director Robert Andrew LaFleur - Senior Vice President of Investor Relations Stewart F.

BTI is navigating headwinds in combustibles and vaping, but gains in oral products and New Categories support modest revenue growth forecasts for 2025. The company's strong free cash flow, safe dividend, and ongoing ITC stake monetization bolster the balance sheet and support shareholder returns. Valuation remains attractive at 7.2x EBITDA, offering significant upside potential if growth improves, especially compared to peers like Altria and Philip Morris.

Stocks can rise on news of addition to the S&P 500 and in the run-up to inclusion.

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ:TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151651&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.